RT Journal Article
SR Electronic
T1 Incubation period of COVID-19 in the “live-house” cluster of accurately known infection events and delay time from symptom onset of public reporting observed in cases in Osaka, Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.23.20110908
DO 10.1101/2020.05.23.20110908
A1 Toshihisa Tomie
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.23.20110908.abstract
AB The incubation period of an infectious disease is very important for control of the disease but estimating the period is not easy because the date of infection is not easy to identify. Accurate incubation period distribution by examining cases in the cluster generated in “live-houses” in Osaka, Japan with known infection events is reported. The distribution of the latent period is also estimated. The modes of incubation and latent periods of COVID-19 in Japan are 4.1 days and 3.3 days, respectively. The mode of the delay time from the onset to reporting is estimated to be 4.7 days, telling that the effects of interventions show up in the number of infections two weeks later after the measures.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialno clinical trialFunding StatementNo funding supportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No clinical trial nor any other interventional study is reportedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred are available from references in the manuscript.